Free Trial

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals logo
$394.53 -2.84 (-0.71%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$393.02 -1.51 (-0.38%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
13
Buy
15

Based on 28 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 13 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$496.05
25.73% Upside
According to the 28 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $496.05. The highest price target for VRTX is $575.00, while the lowest price target for VRTX is $405.00. The average price target represents a forecasted upside of 25.73% from the current price of $394.53.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRTX Analyst Ratings Over Time

TypeCurrent Forecast
9/13/24 to 9/13/25
1 Month Ago
8/14/24 to 8/14/25
3 Months Ago
6/15/24 to 6/15/25
1 Year Ago
9/14/23 to 9/13/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
13 Buy rating(s)
15 Buy rating(s)
16 Buy rating(s)
Hold
13 Hold rating(s)
13 Hold rating(s)
14 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$496.05$497.10$515.04$485.91
Forecasted Upside25.73% Upside27.36% Upside13.08% Upside0.11% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Vertex Pharmaceuticals Stock vs. The Competition

TypeVertex PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.57
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside25.73% Upside17,489.59% Upside10.72% Upside
News Sentiment Rating
Positive News

See Recent VRTX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/11/2025Evercore ISI
3 of 5 stars
Liisa Bayko
Liisa Bayko
Not Rated
Lower TargetOutperform$510.00 ➝ $475.00+21.55%
9/2/2025Raymond James Financial
4 of 5 stars
Danielle Brill
Not Rated
Initiated CoverageMarket Perform
8/6/2025Canaccord Genuity Group
2 of 5 stars
Whitney Ijem
Not Rated
Lower TargetHold$424.00 ➝ $411.00+6.45%
8/6/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$558.00 ➝ $546.00+40.91%
8/6/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight$460.00+22.67%
8/5/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetSector Perform$442.00 ➝ $438.00+11.47%
8/5/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetBuy$520.00 ➝ $490.00+24.70%
8/5/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetSector Perform$430.00 ➝ $405.00+3.86%
8/5/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetBuy$582.00 ➝ $553.00+37.88%
8/5/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetOutperform$557.00 ➝ $530.00+12.22%
8/5/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$535.00 ➝ $485.00+2.70%
8/5/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetHold$494.00 ➝ $455.00-3.66%
8/5/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$550.00 ➝ $478.00+1.21%
8/5/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetEqual Weight$460.00 ➝ $439.00-7.04%
7/14/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$515.00 ➝ $517.00+9.43%
5/23/2025Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
5/7/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformPeer Perform
5/6/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
5/6/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
5/6/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
5/6/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform$550.00 ➝ $503.00+0.56%
5/6/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
3/31/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$555.00 ➝ $567.00+15.08%
2/11/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$435.00 ➝ $467.00+1.35%
1/27/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$535.00 ➝ $533.00+20.72%
12/19/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformMarket Perform
12/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$500.00 ➝ $550.00+19.02%
11/14/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy$575.00+16.25%
7/23/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$450.00 ➝ $500.00+1.60%
6/27/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$545.00+14.98%
6/17/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$465.00 ➝ $550.00+15.48%
2/2/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformMarket Perform
1/31/2024Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeNeutralUnderperform$325.00-25.27%
1/31/2024Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:10 PM ET.


Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 11, 2025. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • The company recently reported earnings per share (EPS) of $4.52, surpassing analyst expectations, which indicates strong financial performance and potential for future growth.
  • Vertex Pharmaceuticals has shown a significant increase in revenue, with a reported $2.94 billion for the latest quarter, reflecting an 11.3% year-over-year growth, suggesting robust demand for its products.
  • The current stock price is around $389, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $519.88.
  • Institutional investors hold a substantial 90.96% of the stock, indicating strong confidence from large financial entities in the company's future prospects.
  • Vertex Pharmaceuticals has a solid return on equity of 23.91%, which demonstrates effective management and profitability, making it an attractive option for investors seeking reliable returns.

Vertex Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • The stock has experienced volatility, with a recent decline of about 1.8%, which may concern investors about short-term price fluctuations.
  • Analysts have mixed ratings on the stock, with some reducing their price targets, indicating uncertainty about future performance and potential market challenges.
  • Despite strong revenue growth, the company has a price-to-earnings ratio of 27.82, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
  • Insider ownership is relatively low at 0.20%, which may raise questions about the alignment of management's interests with those of shareholders.
  • Vertex Pharmaceuticals operates in a highly competitive biotechnology sector, which poses risks related to market share and innovation, potentially impacting future growth prospects.

VRTX Forecast - Frequently Asked Questions

According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $496.05, with a high forecast of $575.00 and a low forecast of $405.00.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 13 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VRTX shares.

According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 25.73% based on their 12-month stock forecasts.

Over the previous 90 days, Vertex Pharmaceuticals's stock had 1 upgrade by analysts.

Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating score for Vertex Pharmaceuticals is 2.57 while the average consensus rating score for "medical" companies is 2.78. Learn more on how VRTX compares to other companies.


This page (NASDAQ:VRTX) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners